Earth Science Tech, Inc. (OTC: ETST) reported financial and operational results for the third fiscal quarter ended December 31, 2025, showcasing significant year-over-year growth. Revenue reached $8.4 million, a 14.1% increase from the prior-year period, while gross profit climbed to $6.4 million, reflecting a robust 76.3% margin. Net income rose 341% to $910,000, and adjusted EBITDA totaled $1.2 million. The company attributed these gains to continued operating leverage and expansion initiatives heading into calendar 2026.
Total assets increased to $8.1 million, and the company ended the quarter with $416,000 in cash, $773,000 in working capital, and no bank debt. During the first nine months of fiscal 2026, Earth Science Tech repurchased and retired 3.7 million shares, signaling confidence in its financial position and future prospects.
Earth Science Tech operates as a strategic holding company focused on value creation through the acquisition, operational optimization, and management of its operating businesses. Its current operations include compounding pharmaceuticals, telemedicine, and real estate development through wholly owned subsidiaries such as RxCompoundStore.com, LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC, Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC, and an 80% interest in MagneChef.
The financial results underscore the company's ability to scale its diversified portfolio and generate improved profitability. With no bank debt and a strong margin profile, Earth Science Tech is positioned to pursue further growth opportunities. For more details, the full press release is available at https://ibn.fm/emIBm.
These developments are particularly noteworthy for investors tracking small-cap growth companies in the life sciences and healthcare sectors. The significant improvement in net income and adjusted EBITDA suggests that the company's operational strategies are yielding tangible results. Additionally, the share repurchase program indicates management's belief in the company's intrinsic value.
As Earth Science Tech continues to execute its business plan, stakeholders will be watching for sustained revenue growth and margin expansion. The company's diversified holdings across pharmaceuticals, telemedicine, and real estate provide multiple avenues for growth, reducing reliance on any single segment.
